Impact of cytotoxic T lymphocytes immunotherapy on prognosis of colorectal cancer patients
Frontiers in Oncology · 16.01.2023 · 13
DOI: 10.3389/fonc.2023.1122669 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 16.01.2023. Verfasst von Yankun Zhu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Expansion and activation of cytotoxic T lymphocytes (CTLs) in vitro represents a promising immunotherapeutic strategy, and CTLs can be primed by dendritic cells (DCs) loaded with tumor-associated antigens (TAAs) transformed by recombinant adeno-associated virus (rAAV). This study aimed to explore the impact of rAAV-DC-induced CTLs on prognosis of CRC and to explore factors associated with prognosis.
Methods
This prospective observational study included patients operated for CRC at Yan’an Hospital Affiliated to Kunming Medical University between 2016 and 2019. The primary outcome was progression-free survival (PFS), secondary outcomes were overall survival (OS) and adverse events. Totally 49 cases were included, with 29 and 20 administered rAAV-DC-induced CTL and chemotherapy, respectively.
Results
After 37-69 months of follow-up (median, 54 months), OS (P=0.0596) and PFS (P=0.0788) were comparable between two groups. Mild fever occurred in 2 (6.9%) patients administered CTL infusion. All the chemotherapy group experienced mild-to-moderate adverse effects, including vasculitis (n=20, 100%), vomiting (n=5, 25%), nausea (n=17, 85%) and fatigue (n=17, 85%).
Conclusions
Lymphatic metastasis (hazard ratio [HR]=4.498, 95% confidence interval [CI]: 1.290-15.676; P=0.018) and lower HLA-I expression (HR=0.294, 95%CI: 0.089-0.965; P=0.044) were associated with poor OS in the CTL group. CTLs induced by rAAV-DCs might achieve comparable effectiveness in CRC patients compare to chemotherapy, cases with high tumor-associated HLA-I expression and no lymphatic metastasis were more likely to benefit from CTLs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of General Surgery, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, China.
- Key Laboratory of Tumor Immunological Prevention and Treatment in Yunnan Province, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, China.
- Department of Pathology, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, China.
Zitieren
APA
Zhu, Y., Meng, M., Hou, Z., Wang, W., Li, L., Guan, A., Wang, R., Tang, W., Yang, F., Zhao, Y., Gao, H., Xie, H., Li, R., & Tan, J. (2023). Impact of cytotoxic T lymphocytes immunotherapy on prognosis of colorectal cancer patients. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1122669
Vancouver
Zhu Y, Meng M, Hou Z, Wang W, Li L, Guan A, et al. Impact of cytotoxic T lymphocytes immunotherapy on prognosis of colorectal cancer patients. Frontiers in Oncology. 2023;13. doi:10.3389/fonc.2023.1122669
BibTeX
@article{Zhu2023,
author = {Zhu, Yankun and Meng, Mingyao and Hou, Zongliu and Wang, Wenju and Li, Lin and Guan, Aoran and Wang, Ruotian and Tang, Weiwei and Yang, Fang and Zhao, Yiyi and Gao, Hui and Xie, Hui and Li, Ruhong and Tan, Jing},
title = {Impact of cytotoxic T lymphocytes immunotherapy on prognosis of colorectal cancer patients},
journal = {Frontiers in Oncology},
year = {2023},
volume = {13},
doi = {10.3389/fonc.2023.1122669}
}
EUVIMED